Download PDF
Pharmacopsychiatry 2003; 36: 2-7
DOI: 10.1055/s-2003-40450
Original Paper
© Georg Thieme Verlag Stuttgart · New York

A Brief History of EGb 761® and its Therapeutic Uses

F. V. DeFeudis1
  • 1Institute for BioScience, Westboro, MA, U.S.A.
Further Information

Publication History

Publication Date:
07 July 2003 (online)

Also available at
    Permissions and Reprints

Dr. Willmar Schwabe III, a German physician-pharmacist, introduced Ginkgo biloba leaf extracts into medical practice in 1965. The earliest publications concerning the therapeutic use of these extracts dealt with their actions on cerebral and peripheral disturbances of blood flow. These extracts led to the development of the extract named EGb 761® (definition see editorial). Clinical studies conducted during the past 25 years have revealed that EGb 761® is useful in treating a wide range of symptoms associated with both early cognitive decline and more severe types of senile dementia of primary degenerative, vascular and mixed origin, as well as peripheral arterial occlusive diseases and various neurosensory disturbances. Laboratory experiments conducted during the past two decades have revealed that several effects of EGb 761® - vasoregulatory, antioxidant, neuroprotective, and anti-stress effects, as well as effects on learning and memory and on gene-regulation - caused by various active constituents of the extract (or their metabolites) act in a complementary manner in producing health-related benefits.

References

  • 1 Ahlemeyer B, Junker V, Huhne R, Krieglstein J. Neuroprotective effects of NV-31, a bilobalide-derived compound: Evidence for an antioxidative mechanism.  Brain Res. 2001;  890 338-342
    PubMedGoogle Scholar
  • 2 Aldridge W N, Street B W, Skilleter D N. Oxidative phosphorylation. Halide-dependent and halide-independent effects of triorganotin and trioganolead compounds on mitochondrial functions.  Biochem J. 1977;  168 353-364
    PubMedGoogle Scholar
  • 3 Amri H, Ogwuegbu S O, Boujrad N, Drieu K, Papadopoulos V. In vivo regulation of the peripheral-type benzodiazepine receptor and glucocorticoid synthesis by the Ginkgo biloba extract EGb 761® and isolated ginkgolides.  Endocrinology. 1996;  137 5707-5718
    CrossrefPubMedGoogle Scholar
  • 4 Anadere I, Chmiel H, Witte S. Hemorheological findings in patients with completed stroke and the influence of a Ginkgo biloba extract.  Clin Hemorheol. 1985;  5 411-420
    PubMedGoogle Scholar
  • 5 Artmann G A, Schikarski C. Ginkgo biloba extract (EGb 761®) protects red blood cells from oxidative damage.  Clin Hemorheol. 1993;  13 529-539
    PubMedGoogle Scholar
  • 6 Attella M J, Hoffman S W, Stasio M J, Stein D J. Ginkgo biloba extract facilitates recovery from penetrating brain injury in adult male rats.  Exp Neurol. 1989;  105 62-71
    CrossrefPubMedGoogle Scholar
  • 7 Auguet M, DeFeudis F V, Clostre F. Effects of Ginkgo biloba on arterial smooth muscle responses to vasoactive stimuli.  Gen Pharmacol. 1982;  13 169-171
    PubMedGoogle Scholar
  • 8 Auguet M, Delaflotte S, Chabrier P E, Braquet P. Ginkgo biloba extract (EGb 761®) and the regulation of vascular tone. In: Clostre F., DeFeudis FV, editors Advances in Ginkgo biloba extract research, vol. 3. Cardiovascular effects of Ginkgo biloba extract (EGb 761®). Paris; Elsevier 1994: pp. 19-26
    Google Scholar
  • 9 Backhauß C, Karkoutly C, Welsch M, Krieglstein J. A mouse model of focal cerebral ischemia for screening neuroprotective drug effects.  J Pharmacol Meth. 1992;  27 27-32
    PubMedGoogle Scholar
  • 10 Barkats M, Venault P, Christen Y, Cohen-Salmon C. Effect of long-term treatment with EGb 761® on age-dependent structural changes in the hippocampi of three inbred mouse strains.  Life Sci. 1995;  56 213-222
    PubMedGoogle Scholar
  • 11 Blume J, Kieser U, Hölscher U. Placebo-kontrollierte Doppelblindstudie zur Wirksamkeit von Ginko-biloba-Spezialextrakt EGb 761® bei austrainierten Patienten mit Claudicatio intermittens.  VASA. 1996;  25 265-274
    PubMedGoogle Scholar
  • 12 Chandrasekaran K, Mehrabian Z, Spinnewyn B, Drieu K, Fiskum G. Neuroprotective effects of bilobalide, a component of the Ginkgo biloba extract (EGb 761®), in gerbil global brain ischemia.  Brain Res. 2001;  922 282-292
    CrossrefPubMedGoogle Scholar
  • 13 Chatterjee S S. Effects of Ginkgo biloba extract on cerebral metabolic processes. In: Agnoli A, Rapin JR, Scapagnini V, Weitbrecht WV, editors Effects of Ginkgo biloba on organic cerebral impairment. London; John Libbey 1985: pp. 5-14
    Google Scholar
  • 14 Chatterjee S S, Gabard B L, Jaggy H EW. Pharmaceutical compositions containing bilobalid for the treatment of neuropathies. U. S. Patent No. 4,571,407 (Feb. 18, 1986). 
    Google Scholar
  • 15 Chatterjee S S, Nöldner M. Behavioural observations demonstrating influences of the extract of Ginkgo biloba (EGb 761®) on some specific central cholinergic systems.  Naunyn-Schmiedeberg’s Arch Pharmacol. 1989;  339 (Suppl.) Abstr. 425
    PubMedGoogle Scholar
  • 16 Chermat R, Brochet D, DeFeudis F V, Drieu K. Interactions of Ginkgo biloba extract (EGb 761®), diazepam and ethyl β-carboline-3-carboxylate on social behavior of the rat.  Pharmacol Biochem Behav. 1997;  56 333-339
    CrossrefPubMedGoogle Scholar
  • 17 Continella G, Drago F. Behavioral effects of Ginkgo-biloba extract. In: Agnoli A, Rapin JR, Scapagnini V, Weitbrecht WV, editors Effects of Ginkgo biloba on organic cerebral impairment. London; John Libbey 1985: pp. 35-42
    Google Scholar
  • 18 DeFeudis F V. Ginkgo biloba extract (EGb 761®): Pharmacological activities and clinical applications. Paris; Elsevier 1991
    Google Scholar
  • 19 DeFeudis F V. Ginkgo biloba extract (EGb 761®): From chemistry to the clinic. Wiesbaden; Ullstein-Mosby 1998
    Google Scholar
  • 20 Delaflotte S, Auguet M, DeFeudis F V, Baranes J, Clostre F, Drieu K. Endothelium-dependent relaxation of rabbit isolated aorta produced by carbachol and by Ginkgo biloba extract.  Biomed Biochim Acta. 1984;  43 (Suppl.) 212-216
    PubMedGoogle Scholar
  • 21 Del Tredici P. Ginkgos and people: A thousand years of interaction.  Arnoldia. 1991;  51 2-15
    PubMedGoogle Scholar
  • 22 Ernst E. Ginkgo biloba in the treatment of intermittent claudication. A systematic search based on controlled studies in the literature [In German].  Fortschr Med. 1996;  114 85-87
    PubMedGoogle Scholar
  • 23 Ernst E, Pittler M H. Ginkgo biloba and dementia: A systematic review of double-blind, placebo-controlled trials.  Clin Drug Invest. 1999;  17 301-308
    CrossrefPubMedGoogle Scholar
  • 24 Fitzpatrick D F, Bing B, Rohdewald P. Endothelium-dependent vascular effects of pycnogenol.  J Cardiovasc Pharmacol. 1998;  32 509-515
    CrossrefPubMedGoogle Scholar
  • 25 Gohil K, Moy R K, Farzin S, Maguire J J, Packer L. mRNA expression profile of a human cancer cell line in response to Ginkgo biloba extract: Induction of antioxidant response and the Golgi system.  Free Radic Res. 2000;  33 831-849
    PubMedGoogle Scholar
  • 26 Hellegouarch A, Baranes J, Clostre F, Drieu K, Braquet P, DeFeudis F V. Comparison of the contractile effects of an extract of Ginkgo biloba and some neurotransmitters on rabbit isolated vena cava.  Gen Pharmacol. 1985;  16 129-132
    PubMedGoogle Scholar
  • 27 Hofferberth B. The efficacy of EGb 761® in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation.  Human Psychopharmacol. 1994;  9 215-222
    PubMedGoogle Scholar
  • 28 Itil T, Martorano D. Natural substances in psychiatry (Ginkgo biloba in dementia).  Psychopharmacol Bull. 1995;  31 147-158
    PubMedGoogle Scholar
  • 29 Jaggy H, Koch E. Chemistry and biology of alkylphenols from Ginkgo biloba L.  Pharmazie. 1997;  52 735-738
    PubMedGoogle Scholar
  • 30 Janssens D, Michiels C, Delaive E, Eliaers F, Drieu K, Remacle J. Protection of hypoxia-induced ATP decrease in endothelial cells by Ginkgo biloba extract and bilobalide.  Biochem Pharmacol. 1995;  50 991-999
    CrossrefPubMedGoogle Scholar
  • 31 Kanowski S, Herrmann W M, Stephan K, Wierich W, Hörr R. Proof of efficacy of the Ginkgo biloba special extract EGb 761® in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.  Pharmacopsychiat. 1996;  29 47-56
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Kleijnen J, Knipschild P. Ginkgo biloba.  Lancet. 1992;  340 1136-1139
    CrossrefPubMedGoogle Scholar
  • 33 Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency.  Br J Clin Pharmacol. 1992;  34 352-358
    CrossrefPubMedGoogle Scholar
  • 34 Larsen R G, Dupeyron J P, Boulu R G. Experimental models of cerebral ischemia in the rat using microspheres: Study of the effects of two extracts of Ginkgo biloba and naftidrofuryl.  [In French] Thérapie. 1978;  33 651-660
    PubMedGoogle Scholar
  • 35 Le Bars P L, Katz M M, Berman N, Itil T M, Freedman A M, Schatzberg A F. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia.  JAMA. 1997;  278 1327-1332
    CrossrefPubMedGoogle Scholar
  • 36 Letzel H, Haan J, Feil W B. Nootropics: Efficacy and tolerability of products from three active substance classes.  J Drug Dev Clin Pract. 1996;  8 77-94
    PubMedGoogle Scholar
  • 37 Letzel H, Schoop W. Ginkgo biloba extract EGb 761® and pentoxifylline in intermittent claudication: Secondary analysis of clinical studies.  [In German] VASA. 1992;  21 403-410
    PubMedGoogle Scholar
  • 38 Mizuno M, Packer L. Ginkgo biloba extract EGb 761® is a suppressor of AP-1 transcription factor stimulated by PMA.  Biochem Molec Biol Int. 1996;  39 395-401
    PubMedGoogle Scholar
  • 39 Monte M, Davel L E, de Lustig E S. Inhibition of lymphocyte-induced angiogenesis by free radical scavengers.  Free Radic Biol Med. 1994;  17 259-266
    CrossrefPubMedGoogle Scholar
  • 40 Oken B S, Storzbach D M, Kaye J A. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease.  Arch Neurol. 1998;  55 1409-1415
    CrossrefPubMedGoogle Scholar
  • 41 Papadopoulos V, Kapsis A, Li H, Amri H, Hardwick M, Culty M ,. et al . Drug-induced inhibition of the peripheral-type benzodiazepine receptor expression and cell proliferation in human breast cancer cells.  Anticancer Res. 2000;  20 2835-2847
    PubMedGoogle Scholar
  • 42 Pietri S, Maurelli E, Drieu K, Culcasi M. Cardioprotective and antioxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761®).  J Mol Cell Cardiol. 1997;  29 733-742
    CrossrefPubMedGoogle Scholar
  • 43 Pincemail J, Dupuis M, Nasr C, Hans P, Haag-Berrurier M, Anton R ,. et al . Superoxide anion scavenging effect and superoxide dismutase activity of Ginkgo biloba extract.  Experientia. 1989;  45 708-712
    PubMedGoogle Scholar
  • 44 Pittler M H, Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: A meta-analysis of randomized trials.  Am J Med. 2000;  108 276-281
    CrossrefPubMedGoogle Scholar
  • 45 Porsolt R D, Martin P, Lenègre A, Fromage S, Drieu K. Effects of an extract of Ginkgo biloba (EGb 761®) on ”learned helplessness” and other models of stress in rodents.  Pharmacol Biochem Behav. 1990;  36 963-971
    CrossrefPubMedGoogle Scholar
  • 46 Prehn J HM, Krieglstein J. Platelet-activating factor antagonists reduce excitotoxic damage in cultured neurons from embryonic chick telencephalon and protect the rat hippocampus and neocortex from ischemic injury in vivo.  J Neurosci Res. 1993;  34 179-188
    CrossrefPubMedGoogle Scholar
  • 47 Rapin J R, Lamproglou I, Drieu K, DeFeudis F V. Demonstration of the ”anti-stress” activity of an extract of Ginkgo biloba (EGb 761®) using a discrimination learning task.  Gen Pharmacol. 1994;  25 1009-1016
    PubMedGoogle Scholar
  • 48 Sancesario G, Kreutzberg G W. Stimulation of astrocytes affects cytotoxic brain edema.  Acta Neuropath. 1986;  72 3-14
    PubMedGoogle Scholar
  • 49 Schindowski K, Leutner S, Kressmann S, Eckert A, Muller W E. Age-related increase of oxidative stress-induced apoptosis in mice: Prevention by Ginkgo biloba extract (EGb 761®).  J Neural Transm. 2001;  108 969-978
    CrossrefPubMedGoogle Scholar
  • 50 Schneider B. Ginkgo biloba extract in peripheral arterial occlusive disease. Meta-Analysis of controlled clinical studies.  [In German] Arzneimittelforscg. 1992;  42 428-436
    PubMedGoogle Scholar
  • 51 Spinnewyn B, Blavet N, Clostre F. Effet de l’extrait de Ginkgo biloba sur un modèle d’ischémie cérébrale chez la gerbille.  Press Méd. 1986;  15 1511-1515
    PubMedGoogle Scholar
  • 52 Watanabe C M, Wolffram S, Ader P, Rimbach G, Packer L, Maguire J J,. et al . The in vivo neuromodulatory effects of the herbal medicine Ginkgo biloba.  Proc Natl Acad Sci USA. 2001;  98 6577-6580
    PubMedGoogle Scholar
  • 53 Weiss H. Summary of a biometric evaluation of clinical trials intended to provide evidence for the clinical efficacy of Ginkgo biloba extract (EGb 761®). Part I: Indication ”disturbance of cerebral function”. Internal Report, Dr. Willmar Schwabe GmbH & Co Karlsruhe; 1988
    Google Scholar
  • 54 Weiss H, Kallischnigg G. Ginkgo biloba extract (EGb 761®): Meta-analysis of studies of the effects in peripheral arterial occlusive disease.  [In German] Münch Med Wschr. 1991;  133 138-142
    PubMedGoogle Scholar
  • 55 Weitbrecht W U, Jansen W. Primary degenerative dementia: Therapy with Ginkgo biloba extract. Placebo-controlled double-blind and comparative study.  [Article in German] Fortschr Med. 1986;  104 199-202
    PubMedGoogle Scholar
  • 56 Winter E. Effects of an extract of Ginkgo biloba on learning and memory in mice.  Pharmacol Biochem Behav. 1991;  38 109-114
    CrossrefPubMedGoogle Scholar

Dr. Francis V. DeFeudis

Institute for BioScience

153 West Main Street

Westboro, MA 01581

U.S.A

Phone: +1 (508) 898-2689

Fax: +1 (508) 898-2689

Email: defeudis@gis.net

      >